Market Overview:
The global polycystic kidney disease treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of polycystic kidney disease, rising awareness about the available treatments, and technological advancements in the field of polycystic kidney disease treatment. The global polycystic kidney disease treatment market by type is segmented into ANG-3070, CIM-2, CR-8, and others. The ANG-3070 segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and safety profile. The CIM-2 segment is projected to grow at a highest CAGR during the forecast period due its ability to inhibit renal cyst growth and progression. The global polycystic kidney disease treatment market by application is divided into clinic, research center, and hospital segments. The clinic segment accounted for majority share of the overall market in 2017 owing higher adoption rates for early diagnosis and better patient care facilities across developed countries such as U S., Canada Europe Japan etc .
Product Definition:
Polycystic kidney disease (PKD) is a genetic disorder that causes numerous fluid-filled cysts to develop in the kidneys. These cysts can interfere with the kidneys' ability to function properly, leading to kidney failure. Treatment for PKD includes medications and surgery to remove cysts from the kidneys.
ANG-3070:
ANG-3070 is a novel oral Janus kinase (JAK) 2/3 inhibitor developed by Novartis AG. The drug was approved in the EU for the treatment of Polycystic Kidney Disease (PKD) based on phase II clinical trials in 2015 and received full approval from FDA in 2016.
CIM-2:
CIM-2 (calcium and magnesium ions channel 2) is a protein that regulates the excitability of cells. It is mainly found in the membranes of cells, especially in cardiac and smooth muscle cells. The disease causing mutations are located on chromosome 9q34. This gene produces CIM-2 protein which is an electrical ionic calcium channel essential for cell function.
Application Insights:
Based on application, the market is segmented into hospital, clinic and research center, and others. The hospital segment dominated the overall market in terms of revenue in 2017. This can be attributed to a large patient base with PKD that requires chronic dialysis or kidney transplantation therapies for survival. Moreover, this segment dominates the market due to high adoption of advanced technologies such as immunotherapy and gene therapy which are being studied rigorously for treating patients with PKD.
The research center segment is expected to witness lucrative growth over the forecast period owing to increasing R&D initiatives undertaken by various institutions across North America and Europe for developing novel treatment options for polycystic kidney disease (PKD). For instance, researchers at UT Southwestern Medical Center are currently studying ways of using stem cells from adult donors along with induced pluripotent stem cells (iPSCs) as a potential therapeutic option for treating patients suffering from end-stage renal diseases associated with cysts in their kidneys.
Regional Analysis:
North America dominated the global polycystic kidney disease treatment market in 2017. This can be attributed to the presence of a large number of patients suffering from this condition, increasing awareness about PCKD, and availability of effective treatment methods for these patients. Moreover, high healthcare expenditure and rising prevalence are also expected to drive growth during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure in emerging countries like China and India along with growing patient pool suffering from various chronic diseases including diabetes & hypertension which ultimately lead to kidney disorders. In addition, government initiatives for creating awareness about PCKD are also anticipated boost regional market growth during the estimated time span.
Growth Factors:
- Increasing incidence of polycystic kidney disease (PKD)
- Growing awareness about PKD and its treatment options
- Technological advancements in the field of PKD treatment
- Availability of government funding for research on PKD treatments
- Rising demand for renal replacement therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Polycystic Kidney Disease Treatment Market Research Report
By Type
ANG-3070, CIM-2, CR-8, Others
By Application
Clinic, Research Center, Hospital
By Companies
Angion Biomedica Corp, Aptevo Therapeutics Inc, Celgene Corp, Conatus Pharmaceuticals Inc, DiscoveryBiomed Inc, Endocyte Inc, IC-MedTech Inc, Ipsen SA, Kadmon Corp LLC, Madrigal Pharmaceuticals Inc., ManRos Therapeutics, Metabolic Solutions Development Company LLC, Mironid Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Polycystic Kidney Disease Treatment Market Report Segments:
The global Polycystic Kidney Disease Treatment market is segmented on the basis of:
Types
ANG-3070, CIM-2, CR-8, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Research Center, Hospital
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Angion Biomedica Corp
- Aptevo Therapeutics Inc
- Celgene Corp
- Conatus Pharmaceuticals Inc
- DiscoveryBiomed Inc
- Endocyte Inc
- IC-MedTech Inc
- Ipsen SA
- Kadmon Corp LLC
- Madrigal Pharmaceuticals Inc.
- ManRos Therapeutics
- Metabolic Solutions Development Company LLC
- Mironid Ltd
Highlights of The Polycystic Kidney Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ANG-3070
- CIM-2
- CR-8
- Others
- By Application:
- Clinic
- Research Center
- Hospital
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Polycystic Kidney Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for polycystic kidney disease will vary depending on the individual's symptoms and medical history. However, some common treatments for polycystic kidney disease include:nnu2013 Diet modification: Some people with polycystic kidney disease may need to make changes to their diet in order to reduce their risk of developing further health problems. This may involve reducing or eliminating foods that are high in sugar and starch, eating more fruits and vegetables, or following a low-fat or vegetarian diet.nnu2013 Medications: Some people with polycystic kidney disease may require medications in order to manage their symptoms. These medications can help improve blood flow through the kidneys and reduce inflammation associated with the condition.
Some of the key players operating in the polycystic kidney disease treatment market are Angion Biomedica Corp, Aptevo Therapeutics Inc, Celgene Corp, Conatus Pharmaceuticals Inc, DiscoveryBiomed Inc, Endocyte Inc, IC-MedTech Inc, Ipsen SA, Kadmon Corp LLC, Madrigal Pharmaceuticals Inc., ManRos Therapeutics, Metabolic Solutions Development Company LLC, Mironid Ltd.
The polycystic kidney disease treatment market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Polycystic Kidney Disease Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Polycystic Kidney Disease Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Polycystic Kidney Disease Treatment Market - Supply Chain
4.5. Global Polycystic Kidney Disease Treatment Market Forecast
4.5.1. Polycystic Kidney Disease Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Polycystic Kidney Disease Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Polycystic Kidney Disease Treatment Market Absolute $ Opportunity
5. Global Polycystic Kidney Disease Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Type
5.3.1. ANG-3070
5.3.2. CIM-2
5.3.3. CR-8
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Polycystic Kidney Disease Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Research Center
6.3.3. Hospital
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Polycystic Kidney Disease Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Polycystic Kidney Disease Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Polycystic Kidney Disease Treatment Demand Share Forecast, 2019-2026
9. North America Polycystic Kidney Disease Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Research Center
9.4.3. Hospital
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Type
9.7.1. ANG-3070
9.7.2. CIM-2
9.7.3. CR-8
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Polycystic Kidney Disease Treatment Demand Share Forecast, 2019-2026
10. Latin America Polycystic Kidney Disease Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Research Center
10.4.3. Hospital
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Type
10.7.1. ANG-3070
10.7.2. CIM-2
10.7.3. CR-8
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Polycystic Kidney Disease Treatment Demand Share Forecast, 2019-2026
11. Europe Polycystic Kidney Disease Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Research Center
11.4.3. Hospital
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Type
11.7.1. ANG-3070
11.7.2. CIM-2
11.7.3. CR-8
11.7.4. Others
11.8. Basis Pont Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Polycystic Kidney Disease Treatment Demand Share, 2019-2026
12. Asia Pacific Polycystic Kidney Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Research Center
12.4.3. Hospital
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Type
12.7.1. ANG-3070
12.7.2. CIM-2
12.7.3. CR-8
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Polycystic Kidney Disease Treatment Demand Share, 2019-2026
13. Middle East & Africa Polycystic Kidney Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Research Center
13.4.3. Hospital
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Polycystic Kidney Disease Treatment Market Size and Volume Forecast by Type
13.7.1. ANG-3070
13.7.2. CIM-2
13.7.3. CR-8
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Polycystic Kidney Disease Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Polycystic Kidney Disease Treatment Market: Market Share Analysis
14.2. Polycystic Kidney Disease Treatment Distributors and Customers
14.3. Polycystic Kidney Disease Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Angion Biomedica Corp
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Aptevo Therapeutics Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene Corp
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Conatus Pharmaceuticals Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. DiscoveryBiomed Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Endocyte Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. IC-MedTech Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Ipsen SA
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Kadmon Corp LLC
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Madrigal Pharmaceuticals Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. ManRos Therapeutics
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Metabolic Solutions Development Company LLC
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Mironid Ltd
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
